Switching from Long-Term Treatment with Self-Injections to Oral Sildenafil in Diabetic Patients with Severe Erectile Dysfunction

2002 ◽  
Vol 41 (4) ◽  
pp. 387-391 ◽  
Author(s):  
P Perimenis
1992 ◽  
Vol 52 (2) ◽  
pp. 221-229 ◽  
Author(s):  
S. Zambon ◽  
A. Lapolla ◽  
G. Sartore ◽  
C. Gherardingher ◽  
A. Cortella ◽  
...  

2003 ◽  
Vol 170 (1) ◽  
pp. 285-290 ◽  
Author(s):  
A. MELMAN ◽  
W. ZHAO ◽  
K.P. DAVIES ◽  
R. BAKAL ◽  
G.J. CHRIST

1997 ◽  
Vol 2 (4) ◽  
pp. 292-295 ◽  
Author(s):  
Manlio Cocozza ◽  
Massimo Milani ◽  
Tommaso Picano ◽  
Ugo Oliviero ◽  
Nicola Russo ◽  
...  

The ex vivo antiaggregatory activity of picotamide, a dual antithromboxane agent, was assessed to find whether it was maintained in long-term treatment. In a double-blind, placebo-controlled 2-year study, 50 type 2 diabetic patients (35 men and 15 women; mean age 66 ± 5 years) were enrolled and randomly given picotamide, 300 mg t.i.d. or the corresponding placebo. Platelet aggregation studies were performed at baseline and after 1, 3, 6, 12, 18 and 24 months. Compliance to the treatment was assessed by pill count at each visit. Forty-nine patients concluded the study. Starting from month 1, compared with placebo, picotamide-treated patients showed a significant inhibition of agonist-induced (ADP, arachidonic acid and collagen) platelet aggregation (–41%). The antiaggregatory effect was maintained throughout the study. At month 24, in the picotamide group, platelet aggregation was significantly lower compared with placebo (–30%). After 24 months of treatment, 20 out of 23 (86%) picotamide-treated patients showed a significant inhibition of platelet aggregation, whereas the remaining three patients had a normal platelet response. During the study, 12 patients suffered from thrombotic events of death: nine in the placebo group and three in the picotamide group, respectively. It was concluded that picotamide maintains its antiaggregatory effect, in long-term treatment, in more than 85% of patients.


2015 ◽  
Vol 4 (4) ◽  
pp. 371
Author(s):  
Dilip Abraham ◽  
Aroma Oberoi ◽  
Eshani Dewan ◽  
Sangeetha Mohan

<p><strong>Introduction:</strong> Zygomycoses is an angioinvasive infection most commonly seen in immunocompromised and diabetic patients. We undertook this study to determine the prevalence of Zygomycoses, in patients with a suspected Invasive Zygomycoses Infection in a tertiary centre and to identify the most common species isolated from culture.</p><p><strong>Materials and Methods:</strong> A retrospective analysis was done from January 1, 2012 to December 8, 2014; the clinical data of the suspected patients and the positive cultures were collected.</p><p><strong>Results and Discussion:</strong> A total of 50 samples of 27 patients with suspected Zygomycoses were sent during the 3 year period. In 25 of these patients, the samples sent were tissue biopsies from nasal cavity and 2 wound swabs from burns. Of these, 18 tissue biopsies of 13 patients and two wound swabs were detected positive for Zygomycetes. (2-Absidia corymbifera; 1-Rhizopus, 15-Mucor). Of the remaining 12 patients whose cultures were negative, 1–bacterial 1–bacterial sinusitis, 5-Invasive aspergillosis; 6-treated as Invasive fungal infections due to Zygomycetes as the imaging diagnostics and histopathological features favored that diagnosis. The majority of the patients (80%) were diabetic, and the two from the burn unit were under long-term treatment for chronic wound infections. Multiple diagnostic modalities must be used in view of the aggressive nature of the disease, but microbiological diagnosis remains the Gold Standard.</p>


Sign in / Sign up

Export Citation Format

Share Document